Chemotherapy for advanced gastric cancer.
By S. Al-Batran, E. Jäger, M. Scholz. Journal of Clinical Oncology, 2007
1,165 citations recorded by the source corpus.
Subfields: Gastroenterology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/169946b211a1f4382d7720ed04fa20b57516df51
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Wen-long Guan
- Ye-Mei He
- R. Maciejewski
- Ruifeng Xu
- Robert Sitarz
- D. Fan
- Yoon-Koo Kang
- M. Lichinitser
Citations in the corpus
- miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells (2008, background): “Chemotherapy remains the primary treatment for both resectable and advanced gastric cancer as to improving overall survival and quality of life for patients.(2,3) In many cases, however, therapies fail because of multidrug resistance (MDR) of cancer cells either intrinsic or acquired after an initia”
- Gastric cancer: epidemiology, prevention, classification, and treatment (2018, methodology): “Combination of regiments bases traditionally upon a platinum– fluoropyrimidine doublet, but adding an anthracycline has been shown to be beneficial.(101) The most commonly used protocols are ECF (epirubicin, cisplatin, 5-FU), ECX (epirubicin, cisplatin, capecitabine), EOF (epirubicin, oxaliplatin, 5”
- Gastric cancer treatment: recent progress and future perspectives (2023, background): “Systemic chemotherapy is the mainstay treatment for metastatic GC (mGC), with a median overall survival (OS) of ~ 12 months for patients treated with conventional chemotherapy [9].”
- Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. (2009, result): “Triple therapy recently received further support from a meta-analysis which showed a significant overall survival (OS) benefit with triple drug regimens containing 5-FU, an anthracycline and cisplatin compared with FP or 5-FU–anthracycline doublets [5]; however, the interpretation of this analysis, ”